Abstract 2310P
Background
The rapid proliferation of cancer cells leads to abnormal vascularization, creating a hypoxic tumor core in most advanced solid tumors. Recent studies have shown that hypoxia is associated with poor prognosis in cancer patients. Tumor aggressiveness is driven by hypoxia, which confers resistance to many conventional cancer therapies. In the present study, we propose that oxygen nanobubbles can reduce the hypoxic effect on the epithelial-to-mesenchymal transition (EMT) and prevent migration and invasion in non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC).
Methods
Using the sonic cavitation method, we have developed a method to generate bulk oxygen nanobubbles (ONBs) with dipalmitoyl phosphatidylcholine (DPPC) lipid and quantitate mean diameter and number density through nanoparticle tracking analysis and insight. We have treated A549 lung adenocarcinoma and MDA-MB-231 triple-negative breast cancer cell lines with 1% oxygen and ONB. We have also checked its preventive role in the zebrafish tumor xenograft model. We have measured HIF-1a and EMT expression markers by immunoblot and qPCR analysis. Moreover, we have used the 4T1 BALB/c mice tumor xenograft model for further confirmation.
Results
ONB promotes HIF-1α hydroxylation and its proteasomal degradation in hypoxic cancer cells. ONBs treated A549 and MDA-MB-231 cancer cells and an adult zebrafish A549 tumor xenografts showed the downregulation of TGF-β and VEGFA expression at the transcriptional and translational levels, which also led to upregulation of epithelial genes like E-cadherin with down-regulation of mesenchymal genes like N cadherin, Vimentin, Fibronectin. ONB treatment significantly affects cancer cell migration. Also, liposomal ONB administrated 4T1 BALB/c breast tumor xenograft model showed similar results.
Conclusions
ONBs reduce HIF-1 mediated epithelial to mesenchymal transition (EMT) controlled by TGF-b and VEGFA and prevent cellular migration and invasion in solid tumors, particularly NSCLC and TNBC. In conclusion, targeted administration of ONB could be a better therapeutic approach to inhibit the hypoxic detrimental effect, which helps to increase the efficacy of anticancer treatments.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Department of Science and Technology (DST) Project, India (DSTSERB- ECR/2016/000288Department of Science and Technology (DST) Project, India (DSTSERB- DST (Department of Science and Technology) Project India, ECR/2016/000288.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2315P - Clinical and blood immune-inflammatory profiling to decode different patterns of acquired resistance in immunotherapy treated NSCLC patients
Presenter: Giulia Mazzaschi
Session: Poster session 08
2316P - Integrating comprehensive cancer genome profiling into clinical practice in an Italian referral center: Results of the first year of the fpg500 programme
Presenter: Camilla Nero
Session: Poster session 08
2317P - Mutational landscape and therapeutic implications in squamous cell carcinomas
Presenter: Laila Belcaid
Session: Poster session 08
2318P - Value of broad molecular profiling for cancer diagnosis
Presenter: Lars Volker Anton Werstein
Session: Poster session 08
2319P - CADSP: A web tool for comprehensive drug sensitivity analysis in pan-cancer
Presenter: Kexin Li
Session: Poster session 08
2320P - Detection of gene fusion-induced neoepitopes in dedifferentiated liposarcoma
Presenter: Peter Horak
Session: Poster session 08
2321TiP - TEMPLE: Thiopurine enhanced mutations for PD-1/ligand-1 efficacy: A phase Ib/II clinical trial
Presenter: Christine Federspiel Secher
Session: Poster session 08
2322TiP - SOUND: A phase II trial evaluating the efficacy of molecular profiling of circulating ± tumor tissue DNA for salvage-therapy matching in patients with advanced and refractory carcinoma
Presenter: Jakob Riedl
Session: Poster session 08